On November 20, Natera fell 4.11% in Regular Trading, trading at $276.34 per share, with turnover of $55.15 million.
The move aligned with continued market digestion of a filing covering potential resale of up to 68,023 common shares by selling stockholders, alongside recent disclosed share sales by director and co-founder Jonathan Sheena, which have remained a near-term overhang on sentiment.
Background context remains mixed: Natera previously reported third-quarter revenue of $794.0 million, above expectations, and raised full-year revenue guidance to $3.005 billion to $3.035 billion, but EPS of $(0.42) missed consensus. More recently, clinical collaboration progress with Incyte in colorectal cancer supported Signatera expectations, yet that positive backdrop appears insufficient to offset pressure from resale and insider-sale concerns in this session.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments